Chronic lymphocytic leukemia deletion gene 7 (Clld7) is a candidate tumor suppressor on chromosome 13q14. Clld7 encodes an evolutionarily conserved protein that contains an RCC1 domain plus broad complex, tramtrack, bric-a-brac (BTB) and POZ domains.
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For cell cycle analysis, U2OS tet on lines transfected with either empty vector or expressing Clld7 (H661) were seeded into a six-well plate at the density of 5 x 10 4 cells/well. Cells were harvested after induction with 2 µg/ml Dox for three days, washed with phosphate buffered saline (PBS) and fixed in 75% ethanol. DNA was stained with propidium iodide (50 µg/ml) and analyzed with a FACSCalibur system using CellQuest software (Becton Dickinson).
For quantification of γ-H2AX activation in H661 cells, cells were treated with 2 µg/ml Dox for two days, fixed and processed using the γ-H2AX phosphorylation assay kit for flow cytometry (Millipore, #17-344, Billerica, MA). Fixed Cells were incubated with either FITC labeled γ-H2AX antibody or mouse IgG as control at 4ºC overnight followed by propidium iodide staining and analyzed using a FACSCalibur instrument (Becton Dickinson). Data were analyzed using FlowJo software (Tree Star, San Carlos, CA).
Cell proliferation analysis
AlamarBlue (Biosource) was used to assess cell viability/proliferation. H661 cells and control cells were seeded into a 96-well plate at a density of 2,000 cells/well. AlamarBlue was added to the culture medium for 10 hours and the fluorescence signal of the dye was captured in a Wallac VICTOR3 1420 plate reader (Perkin Elmer) and analyzed using the Wallac 1420 program.
To determine the effect of caspase inhibitors on cell viability, H661 and control cells were seeded into a 96-well plate at a density of 2,000 cells/well. Twelve hours after induction with 2 μg/ml Dox, pan-caspase inhibitors QVD-Oph (20 μM) or z-VAD (50 μM)
were added to cells for 48 hours before AlamarBlue staining or Western blot analysis.
To test whether Clld7 induced growth inhibition is p53-dependent, H661 cells were transfected with either p53 siRNA (Thermo Fisher Scientific, L-003329-00-0005) or non- 
Immunological Methods
Immunofluorescence experiments were performed as previously described (23) . The γ-H2AX antibody (Millipore, #05-636) and an Alexa Fluor 488 labeled secondary antibody (Invitrogen, #A11001) was used for γ-H2AX detection. Images were taken with a laser scanning Zeiss Axioskop PCM2000 confocal fluorescence microscope. Cells with >5 γ-H2AX foci were counted as positive. Phase contrast pictures were taken using a Zeiss AxioCam Mrm inverted microscope and processed with AxionVision Rel 4.4 software.
For Western blotting, cells were lysed in 0.5% Nonidet P-40 (NP40), 150 mM NaCl, 50 mM Tris-HCl (pH 7.5), and protease inhibitor cocktail (Roche) and cleared by centrifugation at 4°C at 16,000 g for 5 min. Protein concentrations were determined by the Bradford method (Bio-Rad). 150 μg aliquots were analyzed by SDS-PAGE and transferred to PVDF membranes (Immobilon-P, Millipore). Membranes were blocked for one hour in 5% nonfat dry milk in TNET buffer (200 mM Tris-HCl, 1 M NaCl, 50 mM EDTA, 0.1% Tween 20, pH 7.5) and probed with primary antibodies for one hour.
Antibodies used were α-actin (Chemicon, #MAB1501), α-tubulin (Cell Signalling, #2144), HA (Santa Cruz, #sc-805), CDK7 (Cell Signaling, #2916), γ-H2AX (Millipore, #05-636), GADD45A (Santa Cruz, #sc-797), p53 (Millipore, #CBL404) and Phospho-Ser15-p53 (Cell Signaling, #9286). Secondary antibodies were horseradish peroxidase-linked antimouse or anti-rabbit IgG (GE Healthcare). Detection was done with enhanced chemiluminescence (Perkin Elmer Life Sciences, Inc.) followed by digital acquisition and See supplemental materials and methods for immunoprecipitation.
RNAi transfection
Human foreskin keratinocytes were transfected with 200 pmol of Clld7 specific siRNAs, or a control siRNA duplex (Thermo Fisher Scientific) using the Human Keratinocyte
Nucleofector Kit (Lonza Company).
For the apoptosis resistance experiment, siRNA transfected HFKs were seeded on coverslips. Three days after transfection, cells were treated with 10 μg/ml cisplatin (Sigma) for 23 hours. After treatment, cells were fixed and nuclei were stained as described above. At least 1,000 cells for each condition were counted and cells showing nuclear fragmentation were defined as apoptotic cells.
Statistics
Student unpaired t test or two-way ANOVA analysis was used.
Results
Clld7 copy number is reduced and expression is decreased in human tumor cell lines.
Deletions in the region of chromosome 13q14, where Clld7 is localized, have been detected in various lymphoid neoplasms (5) as well as in solid human tumors (6, 8 (Table S2) . 
Clld7 has growth inhibitory activity in osteosarcoma cells
We next aimed to test the effect of ectopic Clld7 expression in cells with reduced endogenous Clld7 expression. The human osteosarcoma cell line U2OS, which expresses relatively low levels of Clld7, was chosen as a model ( Figure S1A ). U2OS cells were transfected with either a pcDNA3 based expression vector for C-terminally HA-tagged Clld7 or pcDNA 3 vector as a control followed by G418 selection. 
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We next determined the effect of Clld7 expression on the cell cycle profile of U2OS cells.
Flow cytometric analyses revealed a significant increase of cells with sub-G1 DNA content from 1% to 32% at 72 hours of Clld7 expression, representing increased DNA fragmentation upon Clld7 expression ( Figure 3A ; lower panels, 3B). In addition, the percentages of cells in G0/G1 and G2/M dropped from 48% to 30% and 28% to 18%, respectively. In contrast, doxycyline treated control cells showed no increase in the percentage of cells with sub-G1 DNA content and minimal changes in their G0/G1 and G2/M populations (57% to 54% and 22% to 23%, respectively) ( Figure 3A ; upper panels, 3B).
To determine whether the observed increase in the sub G1 population upon doxycyline treatment represents caspase-dependent apoptosis, we treated cells with the pancaspase inhibitors, QVD-Oph or z-VAD. As expected, caspase inhibition partially abrogated the decrease in cell density upon Clld7 expression ( Figure 3C ). Quantification by AlamarBlue staining showed that QVD-Oph and z-VAD significantly increased H661 cell survival cells from 26±1.1% to 64%±7.13 and 45±3.34% (p<0.001), respectively ( Figure 3D ).
Clld7 activates the DNA damage/repair pathway
To investigate the molecular mechanism that may cause apoptosis in response to Clld7 expression, we first evaluated whether the DNA damage/repair pathway may be activated due to expression of Clld7. We performed immunofluorescence staining for Figure   5C ). These results suggest that Clld7 activates the DNA damage/repair pathway at least in part through transcriptional up-regulation of DNA damage/repair pathway genes.
Clld7 depletion in primary human epithelial cells confers resistance to apoptosis
in response to DNA damaging chemotherapy agents.
Given that overexpression of Clld7 decreased cell viability and increased formation of γ- 
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Hoechst 33258 are shown in Figure 6C . Similar results were obtained with three independent HFK populations.
To determine whether Clld7 downregulation in HFKs may inhibit p53 activation, we assessed p53 activation in response to cisplatin treatment in HFKs with siRNA mediated Clld7 depletion. These experiments revealed that Clld7 depletion did not compromise p53 Ser15 phosphorylation or p53 stabilization in HFKs ( Figure 6D ). Hence Clld7 may not directly control the capacity of primary cells to sense DNA damage and activate p53.
Discussion
Chromosome 13q14 deletions are frequently detected in a variety of human tumors suggesting the presence of tumor suppressors in this region. Several genes cloned from 13q14 including ARL11 (25), RGC32 (26), and RFP2 (27, 28) have been reported to inhibit tumor growth. Here we investigated whether Clld7 may also be a 13q14 tumor suppressor candidate. By mining publically available data database, we found that at least one copy of Clld7 is lost in ~50% (319/776) of tumor cell lines that have been examined (Table S2 ). Our analysis of this data set, however, does not provide evidence for Clld7 point mutations in these cell lines. By qRT PCR, expression of Clld7 was shown to be low in multiple tumor cell lines (Figure 1 ). Since analysis of CpG islands on chromosome 13q14.3 revealed no evidence for significant methylation in B-CLL patients (29) , promoter methylation may not significantly contribute to the reduced expression of tumor suppressors in the vicinity of 13q14.
To determine whether Clld7 may be a growth suppressor, we expressed the protein in the U2OS human osteosarcoma line that has relatively low endogenous Clld7 expression. We found that cell growth and survival were greatly inhibited ( Figure 2C, D,) and that this inhibition was independent of p53 tumor suppressor activity ( Figure 2D ). 
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Similar results were also obtained with clones with lower level Clld7 expression of (data not shown) suggesting that the observed growth inhibitory effects were not due to highlevel Clld7 expression.
We noted an increased incidence of nuclear foci of γ-H2AX upon Clld7 expression ( Figure 4A ). Nuclear γ-H2AX foci decorate double strand DNA breaks and thus serve as a marker for activation of the DNA damage/repair pathway (30) . Activation of the DNA damage/repair pathway was detected in precancerous lesions by two independent groups in lung cancer (31) as well as bladder tumor specimens (32) . It is purported that the activation of the DNA damage/repair pathway functions as a cell intrinsic tumor suppressor pathway in early potentially precancerous lesions (33) . Since caspase inhibition inhibits cell death but does not affect the incidence of γ-H2AX nuclear foci ( Figure 4C ), the appearance of these foci does not represent a consequence of nucleosomal DNA fragmentation during apoptosis ( Figure 4D ). Therefore, we hypothesize that Clld7 may exert its tumor suppressive activity by regulating DNA damage responses, which, in turn, may lead to growth inhibition and/or apoptosis.
To molecularly characterize the DNA damage response triggered by Clld7 expression, we investigated mRNA expression of genes that have been implicated in DNA damage/repair. These experiments showed that 17 of 84 genes were transcriptionally up-regulated by Clld7, including GADD45A, GADD153, and GADD34 ( Figure 5A and B).
To rule out that the observed activation of the DNA damage pathway represents a consequence of high-level Clld7 expression, we also performed loss-of-function experiments where we depleted Clld7 in primary human epithelial cells. These experiments revealed that Clld7 depletion caused decreased expression of GADD45A and GADD34 ( Figure 6A ).
Given these results we investigated whether, through targeting the DNA/damage repair Indeed, Clld7 depletion in primary human keratinocytes confers resistance to cisplatin and dampens the apoptotic response through a p53 independent pathway ( Figure 6B , C, D). This finding is consistent with a previous report that GADD45A depletion inhibited apoptosis upon genotoxic insults (34) . Similarly, GADD34 depletion also inhibited apoptosis by cisplatin in human mesothelioma cell lines (35) . Hence we hypothesize that Clld7 depletion bestows resistance to apoptotic stress through down-regulating GADD45A and GADD34 expression in primary cells. Given that, presumably due to allelic loss, Clld7 is expressed at low levels in many tumor cell lines, our results suggest that the Clld7 expression level may be predictor of the sensitivity of tumor cells to chemotherapy.
The molecular basis of transcriptional regulation of DNA damage response genes by Clld7 is unknown. The BTB domain may bind to DNA and reprogram gene transcription as most other conserved BTB proteins (36, 37) . However, consistent with a previous report (14) , we found no evidence for nuclear localization of Clld7 (data not shown).
Nevertheless, we observed that ectopic expression of a Clld7 fragment that consists of the BTB domain more potently suppressed U2OS cell proliferation than the isolated RCC1 domain of Clld7 (data not shown), suggesting that the BTB domain may play an important role in the growth suppressive activity of Clld7. As reported previously, BTB proteins function as substrate specific adaptors for Cullin 3 ubiquitin ligase complexes (17, 18, 38) . Consistent with this notion and in agreement with a recent publication (39), co-immunoprecipitation experiments showed that Clld 7 can associate with cullin 3 (supplemental Figure 4) . The identification of substrate(s) of the Clld7-Cul3 complex may provide insights into the mechanism by which Clld7 regulates DNA damage/repair processes. 
